Potential mechanisms of resistance to venetoclax and strategies to circumvent it

[1] Adams JM(2007)The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 26 1324-1337

[2] Cory S(2014)Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy Nat Rev Mol Cell Biol 15 49-63

[3] Czabotar PE(2004)Cell death: critical control points Cell 116 205-219

[4] Lessene G(2012)Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer Mol Diagn Ther 16 347-356

[5] Strasser A(2014)Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma Clin Adv Hematol Oncol 12 224-229

[6] Adams JM(2012)Circumventing cancer drug resistance in the era of personalized medicine Cancer Discov 2 214-226

[7] Danial NN(2014)Multiplex analysis of anti-apoptotic BCL2 family and caspase 3 activation by microbead arrays Assay Drug Dev Technol 12 190-196

[8] Korsmeyer SJ(2014)Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma Blood 123 4111-4119

[9] Lam LT(2004)Structural biology of the Bcl-2 family of proteins Biochim Biophys Acta 1644 83-94

[10] Zhang H(2015)Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm Clin Lymphoma Myeloma Leuk 15 323-334

[1] Adams JM(2007)The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 26 1324-1337

[2] Cory S(2014)Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy Nat Rev Mol Cell Biol 15 49-63

[3] Czabotar PE(2004)Cell death: critical control points Cell 116 205-219

[4] Lessene G(2012)Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer Mol Diagn Ther 16 347-356

[5] Strasser A(2014)Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma Clin Adv Hematol Oncol 12 224-229

[6] Adams JM(2012)Circumventing cancer drug resistance in the era of personalized medicine Cancer Discov 2 214-226

[7] Danial NN(2014)Multiplex analysis of anti-apoptotic BCL2 family and caspase 3 activation by microbead arrays Assay Drug Dev Technol 12 190-196

[8] Korsmeyer SJ(2014)Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma Blood 123 4111-4119

[9] Lam LT(2004)Structural biology of the Bcl-2 family of proteins Biochim Biophys Acta 1644 83-94

[10] Zhang H(2015)Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm Clin Lymphoma Myeloma Leuk 15 323-334